相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Glucose Variability with Second-Generation Basal Insulin Analogs Glargine 300 U/mL and Degludec 100 U/mL, Evaluated by CGM in People with T1D-The InRange Randomized Controlled Trial
Richard M. Bergenstal et al.
DIABETES (2022)
Comparison of Second-Generation Basal Insulin Analogs: A Review of the Evidence from Continuous Glucose Monitoring
Tadej Battelino et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2021)
6. Glycemic Targets: Standards of Medical Care in Diabetes-2021
DIABETES CARE (2021)
The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Richard I. G. Holt et al.
DIABETES CARE (2021)
Effectiveness and Safety of Insulin Glargine 300 U/ml in Comparison with Insulin Degludec 100 U/ml Evaluated with Continuous Glucose Monitoring in Adults with Type 1 Diabetes and Suboptimal Glycemic Control in Routine Clinical Practice: The OneCARE Study
Ignacio Conget et al.
DIABETES THERAPY (2021)
The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes
John M. Lachin et al.
DIABETES CARE (2021)
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units . mL(-1) and Insulin Degludec 100 units . mL(-1) in Type 1 Diabetes
Paola Lucidi et al.
DIABETES CARE (2021)
Reduction in Diabetic Ketoacidosis and Severe Hypoglycemia in Pediatric Type 1 Diabetes During the First Year of Continuous Glucose Monitoring: A Multicenter Analysis of 3,553 Subjects From the DPV Registry
Martin Tauschmann et al.
DIABETES CARE (2020)
Differences between patients with type 1 diabetes with optimal and suboptimal glycaemic control: A real-world study of more than 30 000 patients in a US electronic health record database
Jeremy H. Pettus et al.
DIABETES OBESITY & METABOLISM (2020)
InRange: Comparison of the Second-Generation Basal Insulin Analogues Glargine 300 U/mL and Degludec 100 U/mL in Persons with Type 1 Diabetes Using Continuous Glucose Monitoring-Study Design
Tadej Battelino et al.
DIABETES THERAPY (2020)
Lower risk of severe hypoglycaemia with insulin glargine 300 U/mLversus glargine 100 U/mLin participants with type 1 diabetes: Ameta-analysisof6-monthphase 3 clinical trials
Thomas Danne et al.
DIABETES OBESITY & METABOLISM (2020)
Effects of insulin degludec and insulin glargineU300on glycaemic stability in individuals with type 1 diabetes: A multicentre, randomized controlled crossover study
Hiroshi Miura et al.
DIABETES OBESITY & METABOLISM (2020)
Prevalence and incidence of type 1 diabetes in the world: a systematic review and meta-analysis
Majid Mobasseri et al.
HEALTH PROMOTION PERSPECTIVES (2020)
Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
Tadej Battelino et al.
DIABETES CARE (2019)
Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials
Roy W. Beck et al.
DIABETES CARE (2019)
State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018
Nicole C. Foster et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2019)
Morning administration of 0.4 U/kg/day insulin glargine 300 U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100 U/mL in type 1 diabetes
T. S. Bailey et al.
DIABETES & METABOLISM (2018)
Optimal Sampling Duration for Continuous Glucose Monitoring to Determine Long-Term Glycemic Control
Tonya D. Riddlesworth et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2018)
SELF BLOOD GLUCOSE MONITORING UNDERESTIMATES HYPERGLYCEMIA AND HYPOGLYCEMIA AS COMPARED TO CONTINUOUS GLUCOSE MONITORING IN TYPE 1 AND TYPE 2 DIABETES
Devna Mangrola et al.
ENDOCRINE PRACTICE (2018)
More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial
Julio Rosenstock et al.
DIABETES CARE (2018)
Association of Time in Range, as Assessed by Continuous Glucose Monitoring, With Diabetic Retinopathy in Type 2 Diabetes
Jingyi Lu et al.
DIABETES CARE (2018)
Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections The DIAMOND Randomized Clinical Trial
Roy W. Beck et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Continuous glucose monitoring detected hypoglycaemia in the Treating to Target in Type 2 Diabetes Trial (4-T)
J. C. Levy et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes
Tim Heise et al.
DIABETES OBESITY & METABOLISM (2017)
Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine
Tim Heise et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
New Insulin Glargine 300 Units.mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units.mL-1
Reinhard H. A. Becker et al.
DIABETES CARE (2015)
Insulin degludec improves glycaemic control with lower nocturnal hypoglycaemia risk than insulin glargine in basal-bolus treatment with mealtime insulin aspart in Type 1 diabetes (BEGIN® Basal-Bolus Type 1): 2-year results of a randomized clinical trial
B. W. Bode et al.
DIABETIC MEDICINE (2013)
Does Glycemic Variability Impact Mood and Quality of Life?
Sue Penckofer et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Fear of hypoglycaemia in adults with Type 1 diabetes
T. Anderbro et al.
DIABETIC MEDICINE (2010)
Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with type 2 diabetes on multiple daily insulin injection therapy
Reinhard Zick et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2007)
分享论文
